Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | TP53 P72R |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
TP53 P72R | breast cancer | predicted - sensitive | Daunorubicin | Phase I | Actionable | In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804). | 16243804 | |
TP53 P72R | sarcoma | sensitive | Doxorubicin + Ifosfamide | Phase I | Actionable | In a Phase I clinical trial, sarcoma patients harboring TP53 P72R mutations had longer progression-free survival after treatment with Cyfos (ifosfamide) and Adriamycin (doxorubicin) (PMID: 23165797). | 23165797 | |
TP53 P72R | lung non-small cell carcinoma | sensitive | Cisplatin + Irinotecan | Phase I | Actionable | In phase I clinical studies, NSCLC patients with TP53 P72R mutations had a longer progression-free survival than wild-type TP53 patients, after combined treatment with Camptosar (irinotecan) and Platinol (cisplatin) (PMID: 18618574). | 18618574 | |
TP53 P72R | estrogen-receptor negative breast cancer | sensitive | Cyclophosphamide + Doxorubicin + Fluorouracil | Phase I | Actionable | In a Phase I clinical trial, breast cancer patients harboring TP53 P72R who were estrogen receptor negative had a more favorable response to Doxil (doxorubicin) in combination with Adrucil (fluorouracil) and Cytoxan (cyclophosphamide) (PMID: 16243804). | 16243804 | |
TP53 P72R | breast cancer | predicted - sensitive | Pegylated liposomal-doxorubicin | Phase I | Actionable | In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804). | 16243804 | |
TP53 P72R | breast cancer | sensitive | Epirubicin | Phase I | Actionable | In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations, who were also hormone receptor negative, demonstrated a favorable response to Ellence (epirubicin) in combination with other chemotherapeutic agents (PMID: 22903472). | 22903472 | |
TP53 P72R | breast cancer | predicted - sensitive | Daunoxome | Phase I | Actionable | In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804). | 16243804 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|